FDA approved Tzield, the first drug that delays type 1 diabetes onset

      Earlier in November, the U.S. Food and Drug Administration approved Tzield (teplizumab-mzwv) injection to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes. Tzield, the anti-CD3 monoclonal antibody binds to certain immune system cells and delays progression to stage 3 type 1 diabetes. It may deactivate the immune cells that attack insulin-producing cells, while increasing the proportion of cells that help moderate the immune response. Tzield is administered by intravenous infusion once daily for 14 consecutive days. The most common side effects of Tzield include decreased levels of certain white blood cells, rash, and headache.